Andrew L. Price Sells 5,042 Shares of Encompass Health Co. (NYSE:EHC) Stock

Encompass Health Co. (NYSE:EHC) CAO Andrew L. Price sold 5,042 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total transaction of $495,578.18. Following the transaction, the chief accounting officer now directly owns 69,164 shares of the company’s stock, valued at approximately $6,798,129.56. This trade represents a 6.79 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Encompass Health Price Performance

NYSE EHC opened at $100.91 on Friday. The stock’s 50-day moving average price is $95.97 and its two-hundred day moving average price is $95.54. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.88. The company has a market cap of $10.17 billion, a PE ratio of 22.62, a PEG ratio of 1.18 and a beta of 0.90. Encompass Health Co. has a 1 year low of $73.02 and a 1 year high of $104.55.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 18.06% and a net margin of 8.48%. On average, analysts predict that Encompass Health Co. will post 4.76 EPS for the current year.

Wall Street Analyst Weigh In

EHC has been the subject of several research analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $116.00 price objective (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $110.00 price objective on shares of Encompass Health in a report on Tuesday, February 11th. KeyCorp upped their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. StockNews.com raised shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Barclays upped their price objective on shares of Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday, February 7th. Ten equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $107.67.

Institutional Trading of Encompass Health

Several institutional investors and hedge funds have recently bought and sold shares of EHC. Cetera Investment Advisers raised its holdings in Encompass Health by 5.7% during the 2nd quarter. Cetera Investment Advisers now owns 12,353 shares of the company’s stock worth $1,060,000 after buying an additional 664 shares during the period. CWM LLC increased its holdings in shares of Encompass Health by 27.8% in the 3rd quarter. CWM LLC now owns 8,164 shares of the company’s stock valued at $789,000 after purchasing an additional 1,776 shares during the period. UMB Bank n.a. increased its holdings in shares of Encompass Health by 387.7% in the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company’s stock valued at $31,000 after purchasing an additional 252 shares during the period. Creative Planning increased its holdings in shares of Encompass Health by 4.1% in the 3rd quarter. Creative Planning now owns 19,086 shares of the company’s stock valued at $1,844,000 after purchasing an additional 743 shares during the period. Finally, V Square Quantitative Management LLC increased its holdings in shares of Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after purchasing an additional 140 shares during the period. Institutional investors and hedge funds own 97.25% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.